EA201792329A1 - METHOD OF MONOMERIZATION OF RECOMBINANT ANTIBODY MOLECULES - Google Patents
METHOD OF MONOMERIZATION OF RECOMBINANT ANTIBODY MOLECULESInfo
- Publication number
- EA201792329A1 EA201792329A1 EA201792329A EA201792329A EA201792329A1 EA 201792329 A1 EA201792329 A1 EA 201792329A1 EA 201792329 A EA201792329 A EA 201792329A EA 201792329 A EA201792329 A EA 201792329A EA 201792329 A1 EA201792329 A1 EA 201792329A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody molecules
- monomerization
- recombinant antibody
- composition
- reducing agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
В настоящем изобретении предлагается способ увеличения процента мономера в композиции молекул рекомбинантно экспрессированного антитела, отличающийся тем, что молекула антитела содержит по меньшей мере один Fv со специфичностью к интересующему антигену, содержащий один VH и один VL, где указанные VH и VL связаны прямо или косвенно через один или несколько линкеров и стабилизируются дисульфидной связью между ними, причем указанный способ включает: a) стадию конверсии обработки композиции денатурирующим агентом, выбранным из мочевины и/или гидрохлорида гуанидина; b) где стадию a) проводят в присутствии восстанавливающего агента или после обработки восстанавливающим агентом.The present invention proposes a method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules, characterized in that the antibody molecule contains at least one Fv with specificity for the antigen of interest, containing one VH and one VL, where said VH and VL are linked directly or indirectly through one or more linkers and are stabilized by a disulfide bond between them, and this method includes: a) the conversion stage of processing the composition with a denaturing agent selected from urea and / or g drohlorida guanidine; b) where stage a) is carried out in the presence of a reducing agent or after treatment with a reducing agent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506870.3A GB201506870D0 (en) | 2015-04-22 | 2015-04-22 | Method |
PCT/EP2016/059051 WO2016170138A1 (en) | 2015-04-22 | 2016-04-22 | Method of monomerisation of recombinant antibody molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201792329A1 true EA201792329A1 (en) | 2018-02-28 |
Family
ID=53299019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792329A EA201792329A1 (en) | 2015-04-22 | 2016-04-22 | METHOD OF MONOMERIZATION OF RECOMBINANT ANTIBODY MOLECULES |
Country Status (17)
Country | Link |
---|---|
US (2) | US10828366B2 (en) |
EP (1) | EP3286204B1 (en) |
JP (1) | JP6898251B2 (en) |
KR (1) | KR20170138552A (en) |
CN (1) | CN108064230B (en) |
AU (1) | AU2016251620A1 (en) |
BR (1) | BR112017021812A2 (en) |
CA (1) | CA2981644C (en) |
CL (1) | CL2017002676A1 (en) |
CO (1) | CO2017010385A2 (en) |
EA (1) | EA201792329A1 (en) |
ES (1) | ES2846732T3 (en) |
GB (1) | GB201506870D0 (en) |
IL (1) | IL254765A0 (en) |
MX (1) | MX2017013376A (en) |
SG (1) | SG11201708151TA (en) |
WO (1) | WO2016170138A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
JP6807326B2 (en) | 2014-12-22 | 2021-01-06 | ユーシービー バイオファルマ エスアールエル | Protein production method |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
MX2021003976A (en) * | 2018-10-11 | 2021-05-27 | Amgen Inc | Downstream processing of bispecific antibody constructs. |
MX2023006650A (en) * | 2020-12-07 | 2023-06-21 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations. |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (en) | 1987-07-01 | 1987-07-01 | Novo Industri As | immobilization |
US5453363A (en) | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
ATE151110T1 (en) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING SITES |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JP3672306B2 (en) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | Heterodimeric receptor library using phagemids |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
ATE275198T1 (en) | 1991-12-02 | 2004-09-15 | Medical Res Council | PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES. |
AU675929B2 (en) * | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
FR2716640B1 (en) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Device for centering and blocking a workpiece with a view to running it in using an expansion lapper. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
ES2366100T3 (en) * | 1999-02-22 | 2011-10-17 | Georgetown University | DIRECTED IMMUNOLIPOSOMES THROUGH AN ANTIBODY FRAGMENT FOR THE SYSTEMS ADMINISTRATION OF GENES. |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
BR122019027966B8 (en) | 2002-05-02 | 2021-07-27 | Wyeth Corp | monomeric calicheamicin derivative/anti-cd22 antibody conjugate and their use |
AU2003223936A1 (en) * | 2002-05-17 | 2003-12-02 | Kobenhavns Universitet | Method for purifying denatured proteins having a desired disulfide bond configuration |
US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
KR101200133B1 (en) | 2004-06-01 | 2012-11-13 | 제넨테크, 인크. | Antibody drug conjugates and methods |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
AU2005299716B2 (en) * | 2004-10-22 | 2012-09-06 | Amgen Inc. | Methods for refolding of recombinant antibodies |
US20070021591A1 (en) | 2005-07-25 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Compositions and methods for protein deaggregation |
EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | Proteinaceous pharmaceuticals and uses thereof |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
US20110144311A1 (en) | 2008-08-14 | 2011-06-16 | Rebecca Chmielowski | Methods for purifying antibodies using protein a affinity chromatography |
US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
CN102224239A (en) * | 2008-09-26 | 2011-10-19 | 先灵公司 | High titer antibody production |
MX2011013417A (en) | 2009-06-25 | 2012-03-29 | Amgen Inc | Capture purification processes for proteins expressed in a non-mammalian system. |
EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
CN102892780B (en) * | 2010-03-17 | 2015-07-29 | 通益制药有限公司 | Obtain the method for bioactive recombinant human g-csf |
TR201903279T4 (en) | 2010-03-25 | 2019-03-21 | Ucb Biopharma Sprl | Disulfide stabilized DVD-IG molecules. |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
WO2012040216A1 (en) * | 2010-09-20 | 2012-03-29 | Bio-Rad Laboratories, Inc. | Dissociation of product-complexed contaminants in chromatography |
US8759617B2 (en) * | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
JP2014527072A (en) * | 2011-09-09 | 2014-10-09 | バイオメド リアルティー, エル.ピー. | Methods and compositions for controlling the assembly of viral proteins |
SG11201401649VA (en) | 2011-11-11 | 2014-07-30 | Ucb Pharma Sa | Albumin binding antibodies and binding fragments thereof |
UA112203C2 (en) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
US20160060291A1 (en) | 2012-03-30 | 2016-03-03 | Biogenomics Limited | Process for renaturation of polypeptides |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
LT3447069T (en) | 2012-11-21 | 2020-12-10 | Janssen Biotech, Inc. | Bispecific egfr/c-met antibodies |
WO2015134785A1 (en) | 2014-03-07 | 2015-09-11 | Bionano Genomics, Inc. | Processing of polynucleotides |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
GB201506870D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
EP3485280A1 (en) | 2016-08-12 | 2019-05-22 | Lonza Ltd | Proteomic analysis of host cell proteins |
-
2015
- 2015-04-22 GB GBGB1506870.3A patent/GB201506870D0/en not_active Ceased
-
2016
- 2016-04-22 US US15/566,307 patent/US10828366B2/en active Active
- 2016-04-22 WO PCT/EP2016/059051 patent/WO2016170138A1/en active Application Filing
- 2016-04-22 KR KR1020177033853A patent/KR20170138552A/en unknown
- 2016-04-22 EA EA201792329A patent/EA201792329A1/en unknown
- 2016-04-22 MX MX2017013376A patent/MX2017013376A/en unknown
- 2016-04-22 CA CA2981644A patent/CA2981644C/en active Active
- 2016-04-22 ES ES16719824T patent/ES2846732T3/en active Active
- 2016-04-22 SG SG11201708151TA patent/SG11201708151TA/en unknown
- 2016-04-22 EP EP16719824.1A patent/EP3286204B1/en active Active
- 2016-04-22 BR BR112017021812A patent/BR112017021812A2/en active Search and Examination
- 2016-04-22 AU AU2016251620A patent/AU2016251620A1/en not_active Abandoned
- 2016-04-22 CN CN201680022972.8A patent/CN108064230B/en active Active
- 2016-04-22 JP JP2017555223A patent/JP6898251B2/en active Active
-
2017
- 2017-09-28 IL IL254765A patent/IL254765A0/en unknown
- 2017-10-11 CO CONC2017/0010385A patent/CO2017010385A2/en unknown
- 2017-10-20 CL CL2017002676A patent/CL2017002676A1/en unknown
-
2020
- 2020-10-23 US US17/078,127 patent/US11786593B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20170138552A (en) | 2017-12-15 |
JP6898251B2 (en) | 2021-07-07 |
AU2016251620A1 (en) | 2017-10-26 |
EP3286204B1 (en) | 2020-11-18 |
CL2017002676A1 (en) | 2018-03-23 |
US11786593B2 (en) | 2023-10-17 |
SG11201708151TA (en) | 2017-11-29 |
CA2981644A1 (en) | 2016-10-27 |
US20180117153A1 (en) | 2018-05-03 |
JP2018515449A (en) | 2018-06-14 |
EP3286204A1 (en) | 2018-02-28 |
CN108064230B (en) | 2021-04-06 |
GB201506870D0 (en) | 2015-06-03 |
WO2016170138A1 (en) | 2016-10-27 |
CO2017010385A2 (en) | 2018-03-20 |
US20210069328A1 (en) | 2021-03-11 |
IL254765A0 (en) | 2017-12-31 |
US10828366B2 (en) | 2020-11-10 |
CN108064230A (en) | 2018-05-22 |
CA2981644C (en) | 2023-07-04 |
MX2017013376A (en) | 2017-12-07 |
BR112017021812A2 (en) | 2018-07-10 |
ES2846732T3 (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792329A1 (en) | METHOD OF MONOMERIZATION OF RECOMBINANT ANTIBODY MOLECULES | |
EA201891983A1 (en) | COMBINED THERAPY WITH ANTIBODIES TO CD73 | |
PE20181805A1 (en) | COMPOSITIONS AND ANTI-TIM-3 ANTIBODIES | |
PE20170665A1 (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
EA201491571A1 (en) | MODIFIED BISPECIFIC IgG4 ANTIBODIES WITH ASYMMETRIC SEQUENCE | |
EA201792325A1 (en) | METHOD OF INCREASING THE INTEREST CONTENT OF A MONOMARIAN ANTIBODY IN FAB-DSFV MULTIMERIC PARTICLES | |
AR104280A1 (en) | COMBINATION THERAPY WITH COAGULATION FACTORS AND MULTI-SPECIFIC ANTIBODIES | |
EA201792221A1 (en) | ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION | |
BR112017014308A2 (en) | bispecific antibodies to plasma kallikrein and factor xii | |
EA201591153A1 (en) | ANTIBODIES CONNECTING TL1A AND THEIR APPLICATION | |
PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
EA202091747A1 (en) | ANTIBODY B7-H4 COMPOSITIONS | |
EA201891990A1 (en) | SLIP PROTEINS BASED ON RECOMBINANT FOLLYSTATIN AND FC-FRAGMENT AND THEIR APPLICATION IN THE TREATMENT OF MUSCULAR DYSTROPHY DYUSHEN | |
EA202092420A1 (en) | ANTIBODY AGAINST PD-L1 AND ITS APPLICATION | |
UA120047C2 (en) | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof | |
EA201790816A1 (en) | ANTIBODIES THAT ARE ASSOCIATED WITH CCR6 AND APPLICATION OPTIONS FOR THE INDICATED ANTIBODIES | |
CL2016001028A1 (en) | High affinity and stable aggregation antibodies based on variable domains of vl and derivatives of vhh. | |
AR118763A1 (en) | MONOCLONAL ANTIBODY SPECIFICALLY JOINING GITR | |
EA201991464A1 (en) | ANTIBODY TO α-SINUCLEIN AND ITS APPLICATION | |
EA201990895A1 (en) | ANTIBODIES TO O1 AND OPTIONS OF THEIR APPLICATION | |
MX2022014852A (en) | METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES. | |
PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
EA202191666A1 (en) | ANTIBODIES TO IL-27 AND THEIR USE | |
EA201891529A1 (en) | COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF OVARIAN CANCER | |
EA201691414A1 (en) | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 AND METHODS OF THEIR APPLICATION |